COMBinATion Nivolumab and ASTX727 (decitabine and cedazuridine) for treatment of primary GlioBlastoma
Latest Information Update: 03 Apr 2024
At a glance
- Drugs Cedazuridine/decitabine (Primary) ; Nivolumab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Acronyms COMBAT-GB
Most Recent Events
- 07 Mar 2024 Recruitment end date is 31 March 2026 ,according to ISRCTN: Current Controlled Trials record.
- 23 Jan 2024 New trial record
- 19 Jan 2024 Status changed from not yet recruiting to recruiting.